AstraZeneca PLC ADR (AZN)

68.34
+0.37(+0.54%)
After Hours
66.59
-1.75(-2.56%)
- Real-time Data
  • Volume:
    3,957,755
  • Day's Range:
    68.28 - 68.80
  • 52 wk Range:
    52.65 - 71.70

AZN Overview

Prev. Close
67.97
Day's Range
68.28-68.8
Revenue
43.01B
Open
68.5
52 wk Range
52.65-71.7
EPS
1.32
Volume
3,957,755
Market Cap
212.82B
Dividend (Yield)
1.42
(2.08%)
Average Volume (3m)
6,255,680
P/E Ratio
99.63
Beta
0.168
1-Year Change
24.53%
Shares Outstanding
1,549,528,211
Next Earnings Date
02 Feb 2023
What is your sentiment on AstraZeneca ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR News

AstraZeneca PLC ADR Analysis

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Employees
83100

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company’s marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Analyst Price Target

Average73.92 (+8.17% Upside)
High80
Low54.5
Price68.34
No. of Analysts6
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellSellStrong BuyStrong BuyStrong Buy
SummaryStrong SellNeutralStrong BuyStrong BuyStrong Buy
  • Thanks you AstraZ. Bullish. management services.
    0
    • 54 to 64 bullish sentiments again volatility trading
      0
      • $68 in 1 month
        4
        • Do you this will grow as EU has approved their Covid vaccine?
          0
          • will reach 100 in 6 months time
            0
            • I think the vaccine is nothing next to the antibody coctail, known as AZD7442 that Astra is working on at the momenthttps://www.reuters.com/article/health-coronavirus-astrazeneca-antibody-idUSKBN28100E
              0
              • Good buy in the long term.
                1
                • https://www.wsj.com/articles/astrazeneca-agrees-to-buy-alexion-for-39-billion-11607778687?redirect=amp#click=https://t.co/EeYlRyEn3g
                  0
                  • I expect it to reach $ 100 next month
                    1
                    • for super rich returns
                      0